NCT00367601 - Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

December 31, 2008

Conditions

Lung Cancer

Interventions

DRUG

Erlotinib

Erlotinib 150 mg qd days 1-21

DRUG

Bevacizumab

Bevacizumab 15 mg/kg IV, day 1

Trial Locations (13)

Oncology Partners Network, Cincinnati

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

Community Regional Cancer Center, Indianapolis

Northern Indiana Cancer Research Consortium, South Bend

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

Medical Consultants, P.C., Muncie

Cancer Care Center of Southern Indiana, Bloomington

Oncology Hematology Associates of SW Indiana, Evansville

Arnett Cancer Care, Lafayette

Horizon Oncology Center, Lafayette

Medical & Surgical Specialists, LLC, Galesburg

Methodist Cancer Center, Omaha